Hapvida Participacoes e Investimentos (HAPV3) Q3 2025 earnings summary

Executive summary

• Net revenue reached R$7.8 billion in Q3 2025, up 6.0% year-over-year and 1.3% sequentially, driven by health plan price adjustments and beneficiary growth.

• Adjusted EBITDA was R$746.4 million (9.6% margin), down 2.1% year-over-year; excluding one-offs, adjusted EBITDA was R$613 million.

• Adjusted net income reached R$338 million, up 4.1% year-over-year; excluding one-offs, adjusted net income was R$249.8 million.

• Health beneficiaries increased by 12.6k sequentially, totaling 8,868.9k, with robust corporate growth but net reductions in São Paulo and Rio de Janeiro due to competition.

• Customer satisfaction and quality of care metrics improved, including ANS ranking, IGR, and lower complaint rates.

Financial highlights

• Net revenue was R$7,775 million, with a 6.0% year-over-year increase.

• Cash MLR was 75.2%, up 130–144 bps year-over-year and quarter-over-quarter, reflecting higher utilization and seasonality.

• Adjusted EBITDA margin was 9.6% (reported) and 7.9% (excluding one-offs).

• Net debt increased to R$4.25 billion, with leverage at 1.00x EBITDA LTM.

• CapEx was R$225 million, up 14.1% sequentially and 24.6% year-over-year.

Outlook and guidance

• Margin recovery and cost dilution are expected as new units mature, occupancy increases, and pricing adjustments averaging 10% take effect.

• Management expects MLR pressure to be transitory, with benefits from network expansion and operational improvements anticipated throughout 2026.

• Financials are based on IFRS 4 for comparability; future results may differ under IFRS 17.